Gene expression profiling in AML with normal karyotype: A multicenter study investigating molecular markers in 251 cases

ABSTRACT: Acute myeloid leukemia (AML) is a heterogeneous disease and AML with normal karyotype (AML-NK) is categorized as an intermediate-risk group. Over the past years molecular analyses successfully identified biomarkers that will further allow to dissecting clinically meaningful subgroups in this disease. Thus far, somatic mutations were identified which elucidate the disturbance of cellular growth, proliferation, and differentiation processes in hematopoietic progenitor cells. In AML-NK, acquired gene mutations with prognostic relevance were identified for FLT3, CEBPA, and NPM1. FLT3-ITD mutations were associated with short relapse-free and overall survival, while mutations in CEBPA or NPM1 (without concomitant FLT3-ITD) had a more favorable outcome. Here, we present a multicenter study invest

ORGANISM(S): Homo sapiens

SUBMITTER: Hans-Ulrich Klein 

PROVIDER: E-GEOD-15434 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress